FDA
-
-
-
-
-
-
-
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Goldman on Viridian (VRDN): 'believes the market can potentially grow ~2-3x at peak due to veli's and '003's potential to expand use in chronic TED'
-
-
-
-
-
-
-
Viridian completes enrollment in phase 3 thyroid eye disease trials
-
-
-
-
-
-
-
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
-
-
-
-
-
-
-
Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates
-
-
-
-
-
-
-
Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
-
323,549 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

